Loading…
Reported covered position: Communications Staff, House Minority Leader Richard Gephardt; Chief of Staff, Rep. Patrick Kennedy; and Chief of Staff, Rep. Linda Sanchez.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · second_quarter · 2A
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Source: Senate LDA
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Inflation Reduction Act of 2022
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
HELP Copays Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Cures 2.0 Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Access to Prescription Digital Therapeutics Act of 2022
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
9–8–8 and Parity Assistance Act of 2022
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Seniors Prescription Drug Relief Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Neuroscience Center of Excellence Act of 2021
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Access to Prescription Digital Therapeutics Act of 2022
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Mental Health Reform Reauthorization Act of 2022
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · first_quarter · 1A
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · third_quarter · Q3
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · second_quarter · Q2
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · first_quarter · Q1
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2022 · third_quarter · Q3
S. 4170, Mental Health Reform Reauthorization Act of 2022; H.R. 7232, 9-8-8 and Parity Assistance Act of 2022; HR 6000, Cures 2.0 Act; S.3427, the Neuroscience Center of Excellence Act of 2021; HR 5801, HELP Copays Act; Mental Health Reform Act reauthorization; H.R. 5376, Inflation Reduction Act of 2022 (provisions related to pharmaceuticals); issues relating to diversity in clinical trials, agitation in Alzheimers disease, chronic kidney disease and early detection, PTSD, and mental health as a chronic condition.
Access to Prescription Digital Therapeutics Act of 2022 (S.3791/HR 7051); Due Process Continuity of Care Act (S.2697); Seniors Prescription Drug Relief Act (S.2327); and issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE